http://www.medpagetoday.com/PainManagement/
The FDA has issued its finalized guidance for industry on the development of abuse-deterrent opioids, the agency announced today…
It does not, however, mandate that all new opioids must contain abuse-deterrent mechanisms, and the agency noted that each new product will be considered on a case-by-case basis…
During a press briefing, deputy director of FDA regulatory programs Douglas Throckmorton, MD, said the agency is working with 30 companies interested in developing abuse-deterrent opioids. “The FDA is focused on supporting development” of these products, he said…
Currently four opioids have abuse-deterrent labeling: Targiniq, Hysingla, and reformulated Oxycontin from Purdue Pharma, as well as abuse-deterrent Embeda from Pfizer. Opana and Zohydro have abuse-deterrent formulations, but the FDA did not grant such a label to either product.
Dan Cohen, chair of the Abuse Deterrent Coalition, told MedPage Today that the guidance is a “positive first step,” but added that his organization will “continue to advocate that all Schedule II [opioids] should be required to have an FDA-approved abuse-deterrent formulation.”
This is the future of pain medications. Who will want to put money into researching any drug that’s not formulated with an abuse-deterrent? No one. And how successful are abuse-deterrent formulations in combating drug abuse? If we’re talking about drug abuse in those who suffer from addiction, not very successful at all. All you have to do to get around the deterrent is look it up in the internet. Or addicts just switch to another drug, like heroin.
In fact, you can easily tie the increase in overdoses to these abuse-deterrent drugs, as people are then sometimes forced to use street drugs that have no oversight at all.
https://painkills2.wordpress.com/2014/12/19/7242014-a-reminder-of-the-promise-and-limitations-of-abuse-deterrent-properties/
Like this:
Like Loading...